0001477932-26-003159
SEC filingBioCorRx reported Q1 revenue of $214.5K from Lucemyra distribution alongside a strong 88.3% gross margin, but operating losses of -$956.0K and net loss of -$831.2K reflect elevated expenses and R&D investments amid ongoing cash burn of -$433K.
BioCorRx Inc. generated revenue of $214.5K in Q1 2026, reflecting its distribution model for Lucemyra following the 2025 asset purchase. This drove gross profit to $189.4K, achieving an 88.3% gross margin. The high margin stems from cost of goods sold comprising primarily direct materials, direct labor, and allocated manufacturing overhead based on normal production capacity, underscoring the efficiency of the distribution approach without heavy production burdens.
Net income came in at -$831.2K, or -$0.03 diluted EPS, as the company navigates these expense dynamics. Management's discussion highlights the need for ongoing capital raises through common stock placements or outside financing to execute the business plan, given the dependency on external funding.
Overall, factors like market demand for services, material pricing fluctuations, and competition could influence results. The quarter demonstrates revenue potential from Lucemyra while emphasizing expense discipline and funding access as keys to sustaining operations and R&D momentum.